Click
Chat
 
Du kan vedhæfte PDF, JPG, PNG, DOC(X), XLS(X) og TXT-filer. Klik på ikonet, vælg fil og vent til upload er færdig før du indsender eller uploader endnu en fil.
60
Vedhæft Send
Historik

Vælg chat via ovenstående menu
Luk reklame

DANMARKS STØRSTE INVESTORSITE MED DEBAT, CHAT OG NYHEDER

Cantargia - Kempens Catalyst picks for Q2'21


92508 Helge Larsen/PI-redaktør 2/4 2021 11:11
2
Oversigt

Fra Kempens Industri rapport - Life Scienes - update Q2 2021

Cantargia: Update PDAC (pot. at ASCO) could trigger sentiment recovery

We initiated coverage on Cantargia just a few weeks after seeing the share price taking a hard hit following a phase III failure of competitor Novartis.

We see limited read-through to Cantargia and deem the sell-off overdone, asi) lead compound CAN04 has a broader mode of action compared to Novartis'canakinumab, and ii) the setting where Novartis failed (2L/3L NSCLC) is are cognizable difficult indication, currently not key to the CAN04 story.

In our view,the main indication for CAN04 is 1L PDAC, where we see a straight path forward backed by encouraging interim phase II data showing that a combination with GA in1L PDAC resulted in partial responses in 8/20 patients (40% ORR).

Updated results (incl. more patients, PFS, DOR, biomarkers) are expected in H1'21 (pot. at ASCO).These results will not only be used to design a pivotal phase III trial, but we alsobelieve meaningful PFS and/or DOR (historically in this setting ~23% ORR, mOS8.5m, mPFS 5.5m) could trigger the stock to make up lost ground.



TRÅDOVERSIGT